In the neoadjuvant context of ICBs, tumor-specific CD8+ T cells isolated from non-major pathological response patients expressed high levels of genes associated with T cell dysfunction, such as TOX2, CTLA-4, TIM-3, and CD39. This evidence concerns the gene CD8A and neoplasm.